B-Cell Non-Hodgkin Lymphoma | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Non-Hodgkin lymphoma includes B-cell lymphoma. A class of cancers that impact the immune system is referred to as B-cell lymphoma. 85% of non-Hodgkin lymphomas, the most prevalent cancer in the US, are B-cell lymphomas. The majority of cases (42.5%) were of developmental diffuse large B-cell lymphoma. Burkitt's lymphoma (22% of cases), B and T lymphocytic leukemia/carcinoma lymphoma (11% of cases vs. 2.9%), as well as exogenous NK/T cell lymphoma. Early large B-cell lymphomas are those that begin in the mediastinum, which is the area between the lungs. Six cycles of CHOP and rituximab (R-CHOP) chemotherapy are the standard course of treatment.

Description

Non-Hodgkin lymphoma includes B-cell lymphoma. Immune system-related cancers are referred to as B-cell lymphomas. Most non-Hodgkin lymphomas, the most prevalent cancer in the US, are B-cell lymphomas, which make up 85% of all cases. The lymphatic system, a network of lymph nodes, blood vessels, and lymphoid tissues that transports bodily fluids, is where B-cell lymphomas most frequently develop. One of the fluids that the lymphatic system circulates throughout the body is lymph. Lymphocytes are a type of white blood cell. antibodies against infection are made by B lymphocytes or B cells. In order to make room for more B cells, healthy B cells typically die. B-cell lymphoma is a condition in which normally healthy B cells change into uncontrollably growing cancer cells. In time, healthy cells are outgrown by cancer cells due to their rapid growth. Additionally, cancerous cells can spread to the bone marrow, spleen, or other organs.

B-Cell Non-Hodgkin Lymphoma (Epidemiology)

The most prevalent subtype (42%) was developmental diffuse large B-cell lymphoma. Additionally prevalent subtypes included Burkitt's lymphoma (2.2%), B and T lymphocytic leukemia/carcinoma lymphoma (1.1% vs. 2.9%) and exogenous NK/T cell lymphoma (2.2%). NHL was the 11th most prevalent cancer in Europe in 2012, with 3% of all cancer diagnoses occurring there. The growth of NHL in particular regions appears to be influenced by specific local geographic factors. For instance, Burkitt's lymphoma caused by the Epstein-Barr virus (EBV) is the most frequent type of childhood cancer in tropical Africa. Heavy chain disease (alpha), a B-lymphocyte disease prevalent in the Middle East, is characterized by diffuse thickening of the small intestine brought on by lymphatic infiltration as a result of inadequate secretion of immunoglobulin A (IgA) heavy chains. Rarely do people of non-Mediterranean ethnicity experience this clinical entity. While follicular lymphoma is uncommon in the Caribbean, Africa, China, Japan, and the Middle East, it is more common in North America and Europe.

B-Cell Non-Hodgkin Lymphoma -Current Market Size & Forecast Trends

The B-Cell Non-Hodgkin Lymphoma (NHL) market is currently valued at approximately USD 16.1 billion as of 2021, and it is projected to continue growing significantly, with estimates indicating a potential market size of around USD 25 billion by 2035. This growth is driven by several factors, including the increasing prevalence of B-cell lymphomas, advancements in treatment options such as CAR-T cell therapies and monoclonal antibodies, and a rising focus on personalized medicine. The market is expected to experience a compound annual growth rate (CAGR) of about 5.83% from 2024 to 2034. Key trends include the expansion of existing therapies into earlier treatment lines, the integration of innovative diagnostic techniques like next-generation sequencing, and a growing emphasis on patient-centered care approaches that improve treatment outcomes. Additionally, ongoing clinical trials are likely to introduce new therapies and combinations that enhance efficacy and address unmet medical needs within this patient population.

Large B-cell lymphomas are thought to have their earliest stages in mediastinum-based lymphomas. 6 cycles of CHOP and rituximab (R-CHOP) chemotherapy are the standard course of treatment. Then, mediastinal radiation therapy could be given. After chemotherapy, a PET/CT scan is typically performed to check for breast lymphoma. Without further treatment, the patient can be watched if the PET/CT scan shows no evidence of active lymphoma. Radiation therapy may be required if the PET/CT scan is positive, which could mean that lymphoma is active. Before beginning radiation therapy, doctors may occasionally request a biopsy of a breast tumor to confirm the presence of lymphoma. DA-EPOCH-R, a six-cycle chemotherapy regimen that combines vincristine, prednisone, and rituximab with modified etoposide, doxorubicin, and cyclophosphamide, is another option for treatment. This regimen typically does not involve radiation therapy. Another chemotherapy regimen (possibly involving a stem cell transplant) or immunotherapy, such as CAR T-cell therapy or immune checkpoint inhibitors, may be available if PML recurs or does not respond to chemotherapy.

Report Highlights

B-Cell Non-Hodgkin Lymphoma - Current Market Trends

B-Cell Non-Hodgkin Lymphoma - Current & Forecasted Cases across the G8 Countries

B-Cell Non-Hodgkin Lymphoma - Market Opportunities and Sales Potential for Agents

B-Cell Non-Hodgkin Lymphoma - Patient-based Market Forecast to 2035

B-Cell Non-Hodgkin Lymphoma - Untapped Business Opportunities

B-Cell Non-Hodgkin Lymphoma - Product Positioning Vis-a-vis Competitors' Products

B-Cell Non-Hodgkin Lymphoma - KOLs Insight